These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 10495331)

  • 21. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection.
    Johansen HK; Nørregaard L; Gøtzsche PC; Pressler T; Koch C; Høiby N
    Pediatr Pulmonol; 2004 May; 37(5):427-32. PubMed ID: 15095326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Van Stormbroek B; Zampoli M; Morrow BM
    Pediatr Pulmonol; 2019 Apr; 54(4):393-398. PubMed ID: 30656856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.
    Heltshe SL; Khan U; Beckett V; Baines A; Emerson J; Sanders DB; Gibson RL; Morgan W; Rosenfeld M
    J Cyst Fibros; 2018 May; 17(3):341-347. PubMed ID: 29110966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Proesmans M; Vermeulen F; Boulanger L; Verhaegen J; De Boeck K
    J Cyst Fibros; 2013 Jan; 12(1):29-34. PubMed ID: 22762867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term clinical outcomes of 'Prairie Epidemic Strain'
    Somayaji R; Lam JC; Surette MG; Waddell B; Rabin HR; Sibley CD; Purighalla S; Parkins MD
    Thorax; 2017 Apr; 72(4):333-339. PubMed ID: 27682327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolation measures for prevention of infection with respiratory pathogens in cystic fibrosis: a systematic review.
    Festini F; Buzzetti R; Bassi C; Braggion C; Salvatore D; Taccetti G; Mastella G
    J Hosp Infect; 2006 Sep; 64(1):1-6. PubMed ID: 16835001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
    Milla CE; Chmiel JF; Accurso FJ; VanDevanter DR; Konstan MW; Yarranton G; Geller DE;
    Pediatr Pulmonol; 2014 Jul; 49(7):650-8. PubMed ID: 24019259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of Pseudomonas aeruginosa eradication regimens on chronic colonization and clinical outcomes in pediatric patients with cystic fibrosis.
    Nayir Buyuksahin H; Yalçın E; Emiralioglu N; Hazırolan G; Ademhan Tural D; Ozsezen B; Sunman B; Guzelkas I; Dogru D; Ozcelik U; Kiper N
    Pediatr Int; 2022 Jan; 64(1):e15249. PubMed ID: 36321341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eradication of early Pseudomonas aeruginosa infection.
    Høiby N; Frederiksen B; Pressler T
    J Cyst Fibros; 2005 Aug; 4 Suppl 2():49-54. PubMed ID: 16023416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.
    Connett GJ; Pike KC; Legg JP; Cathie K; Dewar A; Foote K; Harris A; Faust SN
    Ther Adv Respir Dis; 2015 Dec; 9(6):272-80. PubMed ID: 26341118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous alternating inhaled antibiotic therapy in CF: A single center retrospective analysis.
    Van de Kerkhove C; Goeminne PC; Kicinski M; Nawrot TS; Lorent N; Van Bleyenbergh P; De Boeck K; Dupont LJ
    J Cyst Fibros; 2016 Nov; 15(6):802-808. PubMed ID: 27720321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.
    Merlo CA; Boyle MP; Diener-West M; Marshall BC; Goss CH; Lechtzin N
    Chest; 2007 Aug; 132(2):562-8. PubMed ID: 17646236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study.
    Maliniak ML; Stecenko AA; McCarty NA
    J Cyst Fibros; 2016 May; 15(3):350-6. PubMed ID: 26610860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-infections with Pseudomonas aeruginosa in patients with cystic fibrosis attending the Warsaw Centre.
    Milczewska J; Wołkowicz T; Zacharczuk K; Kwiatkowska M
    Dev Period Med; 2015; 19(1):60-5. PubMed ID: 26003071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.
    Rosenfeld M; Emerson J; McNamara S; Joubran K; Retsch-Bogart G; Graff GR; Gutierrez HH; Kanga JF; Lahiri T; Noyes B; Ramsey B; Ren CL; Schechter M; Morgan W; Gibson RL;
    Pediatr Pulmonol; 2010 Sep; 45(9):934-44. PubMed ID: 20597081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center.
    Denton M; Kerr K; Mooney L; Keer V; Rajgopal A; Brownlee K; Arundel P; Conway S
    Pediatr Pulmonol; 2002 Oct; 34(4):257-61. PubMed ID: 12205566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective prevention of Pseudomonas aeruginosa cross-infection at a cystic fibrosis centre - results of a 10-year prospective study.
    Wiehlmann L; Cramer N; Ulrich J; Hedtfeld S; Weissbrodt H; Tümmler B
    Int J Med Microbiol; 2012 Mar; 302(2):69-77. PubMed ID: 22196973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients.
    Høiby N; Pedersen SS
    Acta Paediatr Scand; 1989 May; 78(3):395-404. PubMed ID: 2787093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.